Cariprazine and Rifapentine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 16, 2026 · Source data updated Jul 16, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Rifapentine
Cariprazine
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Rifapentine (Priftin) is a strong "speed-up" drug for the liver. It can make your body process certain medicines faster than normal. Cariprazine (Vraylar) is broken down by the same liver pathway that rifapentine speeds up.
Here's the tricky part: cariprazine turns into active forms in your body, and that same pathway both creates and removes them. So when rifapentine speeds things up, it's genuinely hard to predict whether your cariprazine will work better, worse, or the same. Because of this uncertainty, the two are usually not recommended together. The good news is your care team can plan around this, so please talk with your doctor or pharmacist before making any changes.
Mechanism: Rifapentine is a potent CYP3A4 inducer; cariprazine is a CYP3A4 substrate whose active metabolites (desmethyl- and didesmethyl-cariprazine) are both formed and cleared via CYP3A4.
- Direction/magnitude: Net effect on total active-moiety exposure is unpredictable because CYP3A4 governs both formation and elimination of the active metabolites; not formally studied.
- Onset: Unspecified; enzyme induction is typically delayed (days to weeks).
- Evidence: Theoretical.
- Management: Combination not recommended per labeling. If unavoidable, monitor closely for loss of efficacy or altered response and individualize therapy.
What happens
Effects on the cariprazine exposure has not been evaluated and the net effect is unclear
Interaction Deep Dive
It is advised against giving cariprazine (which is a substrate of CYP3A4) together with a CYP3A4 inducer. The generation and clearance of cariprazine's active metabolites depend on CYP3A4. How CYP3A4 inducers influence cariprazine exposure has not been studied, so the overall outcome remains uncertain1.
Why it happens (mechanism)
Induction of CYP3A4-mediated metabolism of cariprazine
How to manage this interaction
What your care team may do:
- Because the combined effect can't be predicted, this pairing is generally not recommended, and your team may consider an alternative medication.
- If both are truly needed, your dose may be adjusted and individualized, and your team may monitor you more closely for how well your symptoms are controlled or for any change in side effects.
What you should do: Keep taking both exactly as prescribed unless told otherwise. Let your pharmacist or prescriber know you are on both, and report any worsening mood symptoms or new side effects so they can fine-tune your plan.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Cariprazine and Rifapentine together?
Rifapentine can speed up how your body handles cariprazine, and the overall result is unpredictable, so this combination is usually not recommended. Talk with your doctor or pharmacist before changing anything. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Cariprazine and Rifapentine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Cariprazine and Rifapentine interaction managed?
What your care team may do: Because the combined effect can't be predicted, this pairing is generally not recommended, and your team may consider an alternative medication. If both are truly needed, your dose may be adjusted and individualized, and your team may monitor you more closely for how well your symptoms are controlled or for any change in side effects. What you should do: Keep taking bot… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Cariprazine or Rifapentine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: VRAYLAR(R) oral capsules, cariprazine oral capsules. AbbVie Inc. (per FDA), North Chicago, IL, 2024. DailyMed
Keep reading about Rifapentine
Keep reading about Cariprazine
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist